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SUMMARY
Cancer patients having anti-programmed cell
death-1 (PD-1)/PD ligand 1 (L1)-unresponsive tu-
mors may benefit from advanced immunotherapy.
Double-stranded RNA triggers dendritic cell (DC)
maturation to cross-prime antigen-specific cytotoxic
T lymphocytes (CTLs) via Toll-like receptor 3 (TLR3).
The TLR3-specific RNA agonist, ARNAX, can induce
anti-tumor CTLs without systemic cytokine/inter-
feron (IFN) production. Here, we have developed a
safe vaccine adjuvant for cancer that effectively im-
plements anti-PD-L1 therapy. Co-administration of
ARNAX with a tumor-associated antigen facilitated
tumor regression in mouse models, and in combina-
tion with anti-PD-L1 antibody, activated tumor-spe-
cific CTLs in lymphoid tissues, enhanced CTL infiltra-
tion, and overcame anti-PD-1 resistance without
cytokinemia. The TLR3-TICAM-1-interferon regula-
tory factor (IRF)3-IFN-b axis in DCs exclusively
participated in CD8+ T cell cross-priming. ARNAX
therapy established Th1 immunity in the tumor
microenvironment, upregulating genes involved in
DC/T cell/natural killer (NK) cell recruitment and
functionality. Human ex vivo studies disclosed that
ARNAX+antigen induced antigen-specific CTL prim-
ing and proliferation in peripheral bloodmononuclear
cells (PBMCs), supporting the feasibility of ARNAX
for potentiating anti-PD-1/PD-L1 therapy in human
vaccine immunotherapy.
INTRODUCTION
Blockade of the programmed cell death-1 (PD-1) immune check-
point pathway induces efficient remission in patients with meta-
static cancers (Kamphorst and Ahmed, 2013; Hamid et al., 2013;
Herbst et al., 2014; Tumeh et al., 2014), but responses are
observed in only 20% of patients with all solid tumor types
(Herbst et al., 2014; Tumeh et al., 2014). Preexistence of anti-tu-
mor cytotoxic T lymphocytes (CTLs) and their infiltration into
tumors are a prerequisite for treatment efficacy (Tumeh et al.,
2014). The frequency of high nonsynonymous mutations in
tumors is correlated with the efficacy of PD-1/PD-ligand-1
(PD-L1) blockade therapy and long-term survival of patients
(Rizvi et al., 2015; Schumacher and Schreiber, 2015). Thus,
mutated tumor-associated antigens (TAAs) may be involved in
the generation of anti-tumor CTLs and responses to PD-1/
PD-L1 blockade therapy. Tumor-specific CTLs have been char-
acterized using TAA peptides and tetramers in peptide vaccine
therapy preceding PD-1 checkpoint inhibition (Coulie et al.,
2014). In patients responding to peptide vaccine therapy,
tetramer-positive CTLs are increased in the blood and tumor
sites. Insufficient induction of tumor-specific CTLs would have
been a barrier to establishment of the vaccine therapy.
TAA-specific CTLs are generated in the draining lymph node
(DLN) in line with maturation of antigen (Ag)-presenting dendritic
cells (DCs), coupled with cross-priming, upregulation of major
histocompatibility complex (MHC)/B7s, and production of type
I interferon (IFN) and IL-12, which are induced by signals from
pattern recognition receptors (Steinman and Banchereau,
2007). The majority of vaccines for infectious diseases are natu-
rally effective because both Ag and pattern molecules (adjuvant)
are simultaneously provided to satisfy the above criteria, thereby
facilitating DC maturation (Seya and Matsumoto, 2009). Tumors
are self-originating and essentially lack adjuvant. In the absence
of adjuvant, no response is triggered against the tumor, even
though PD-1/PD-L1 blockade has the potential to replenish
CTLs and restore their function. Currently approved adjuvants,
such as Alum and oil, deviate from the purpose for supporting tu-
mor immunotherapy, because they are inflammasome or mono-
cyte/macrophage stimulators (Eisenbarth et al., 2008; Mbow
et al., 2010). The development of appropriate priming adjuvants
remains an urgent medical need to optimize the high efficacy of
checkpoint therapy.
Poly(I:C) is an adjuvant that targets DCs in DLN and tumor mi-
croenvironments and converts them into the active phenotype,
inducing priming and proliferation of tumor-specific CTLs and
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Figure 1. The TLR3-TICAM-1-IRF3-IFN-b Axis in DCs Is Indispensable for ARNAX-Induced Ag-Specific CD8+ T Cell Priming
(A) OVA-specific CD8+ T cell proliferation in spleen and inguinal LN fromwild-type and knockout mice. Mice were injected s.c. with PBS, OVA, or ARNAX+OVA on
days 0 and 7 (n = 2 per treatment). On day 11, OVA-specific CD8+ T cell proliferation in spleen (left) and inguinal LN (right) was evaluated with the tetramer assay.
Error bars indicate means ± SD. Data are representative of two independent experiments.
(B) IFN-g production by OVA-specific CD8+ T cells in spleen cells. Spleen cells were stimulated with OVA (SL8) or WT1 (Db126) peptide for 3 days and the IFN-g
level in the culture supernatant was measured using CBA.
(legend continued on next page)
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altering the microenvironment from tumor-supporting to tumor-
suppressive (Azuma et al., 2012, 2016; Shime et al., 2012,
2017). Numerous clinical trials have been conducted with
poly(I:C) (Galluzzi et al., 2012). One critical point of poly(I:C) is
to provoke systemic cytokine toxicity (Levine et al., 1979; Lamp-
kin et al., 1985). Minimal doses have been applied to prime DCs
with the aim of reducing toxicity, but safe amounts appear insuf-
ficient to evoke the immune response, determined byCTL quality
(Sabbatini et al., 2012). To guarantee proliferation and high qual-
ity of anti-tumor CTLs aswell as efficacy of checkpoint therapy in
non-responsive cancer patients, we should establish non-toxic
priming-phase adjuvants and then construct a synergistic ther-
apy with anti-PD-1/PD-L1 Ab.
Comprehensive genomic and transcriptomic studies have
been conducted on several tumors to determine the features
affecting sensitivity or resistance to checkpoint blockade ther-
apy (Zelenay et al., 2015; Hugo et al., 2016). Innate resistance
properties of non-responding tumors (Hugo et al., 2016) as
well as immunosuppressive tumor microenvironments (Zelenay
et al., 2015) appear to affect the efficacy of checkpoint blockade,
and combination strategies targeting these negative factors
have been proposed to overcome anti-PD-1 resistance (Gajew-
ski et al., 2013; Sharma and Allison, 2015a; Salmon et al., 2016;
De Henau et al., 2016). However, effective measures to over-
come the unresponsiveness to PD-1 blockade in patients with
lower nonsynonymous mutation burden in tumors or low levels
of anti-tumor CTLs remain to be established.
Here, we explored the utility of combination therapy with anti-
PD-L1 Ab and the non-inflammatory adjuvant, ARNAX, targeting
endosomal Toll-like receptor 3 in DCs in a mouse tumor model
(Matsumoto et al., 2015; Seya et al., 2015). Toll-like receptor 3
(TLR3) is highly expressed in professional Ag-presenting mouse
CD8a+ and CD103+ and human CD141+ DCs (Bachem et al.,
2010; Jongbloed et al., 2010). ARNAX co-administered with
TAA facilitated tumor regression in mouse tumor implant
models, and in combination with anti-PD-L1 Ab, promoted full
priming of anti-tumor CTLs and proliferation in DLN and
enhanced CD8+ T cell infiltration into the tumor site, leading
to relief against anti-PD-1 unresponsiveness. Throughout the
therapy, ARNAX elicited efficient anti-tumor immunity with no
cytokinemia.
RESULTS
The TLR3-TICAM-1-Interferon Regulatory Factor 3-IFN-
b Axis in DCs Is Essential for Ag-Specific CTL Priming by
ARNAX
The TLR3-specific adjuvant consisting of 140 bp double-
stranded RNA (dsRNA) capped with phosphorothioated oligo-
deoxynucleotides, designated ARNAX, can induce anti-tumor
CTLs without systemic cytokine/IFN production (Matsumoto
et al., 2015). Here, we determined the signaling cascade of
ARNAX-induced cross-priming using mice depleted of innate
immune receptors/signaling molecules (Figure 1). ARNAX
failed to induce ovalbumin (OVA)-specific CD8+ T cell prolifer-
ation and IFN-g production in spleen and inguinal LN of
Tlr3/, Ticam1/, Irf3/, and Irf3//Irf7/ mice (Figures
1A, 1B, and S1A). In contrast, knockout of Mavs (an adaptor
for RIG-I/MDA5) or Myd88 (an adaptor for TLRs, except
TLR3) did not affect ARNAX-induced CD8+ T cell priming
(Figures 1A, 1B, and S1A), indicating that the TLR3-TICAM-
1-interferon regulatory factor 3 (IRF3) axis is indispensable
for ARNAX-induced cross-priming. ARNAX appears to escape
from recognition by the RNA sensors, RIG-I and MDA5, and
the DNA sensor, TLR9.
Accumulating evidence suggests that type I IFN-signaling is
critical for cross-priming in DCs (Fuertes et al., 2011, 2013; Pan-
tel et al., 2014). In Ifnar/ mice, ARNAX hardly induced OVA-
specific CD8+ T cell proliferation in spleen and inguinal LN,
whereas poly(I:C) that activates both TLR3 and MDA5 (Kato
et al., 2006; Matsumoto and Seya, 2008) induced proliferation
even in the absence of type I IFN signaling (Figures 1C and
S1B). In accordance with this finding, splenocytes from
ARNAX+OVA-treated Ifnar/ mice secreted little or no IFN-g
upon re-stimulation with OVA-specific SL8 peptide in vitro
(Figure 1D). The finding that ARNAX induces IFN-b mRNA
expression in lymphoid tissues without systemic type I IFN
production (Matsumoto et al., 2015) suggests that the TLR3-
TICAM-1-IRF3-IFN-b axis in DCs exclusively participates in
ARNAX-mediated CD8+ T cell priming.
Features of ARNAX-Induced Cytokine Production
Cytokines, including IL-12 and type I IFN, are required for CD8+
T cell priming as a third signal for the development of functional
T cells (Curtsinger and Mescher, 2010; Gerner et al., 2013).
Accordingly, we examined the cytokine profile induced upon
subcutaneous (s.c.) injection of ARNAX in mice. IL-6, tumor ne-
crosis factor alpha (TNF-a), and IFN-b levels induced by ARNAX
were lower than those induced by poly(I:C) (Figure 2A). Recently,
we showed that intraperitoneal (i.p.) injection of poly(I:C) in mice
induced robust serum IL-6, TNF-a, and IFN-b production,
whereas minimal or no induction was observed following i.p.
administration of ARNAX (Matsumoto et al., 2015). The results
were reproducible with those obtained upon intravenous (i.v.)
injection, ARNAX barely induced IL-6, TNF-a, and IFN-b produc-
tion in contrast to poly(I:C) (Figure 2B), reflecting its non-inflam-
matory properties. Notably, the Th1 cytokine, IL-12p40, and
chemokine, IP-10, that recruits natural killer (NK) cells and
CTLs were substantially induced upon s.c. injection of ARNAX,
similar to data obtained with poly(I:C) (Figure 2A), implying that
ARNAX mediates Th1 skewing with less inflammation. Given
that IL-12-stimulated CD8+ T cells express lower levels of
PD-1 upon re-encountering Ag in tumors and survive longer
than type I IFN-stimulated T cells (Gerner et al., 2013), the
ARNAX-induced cytokine profile of IL-12high/IFN-blow may be
an advantage for CD8+ T cells in controlling tumors.
(C) ARNAX-induced cross-priming is dependent on the type I IFN signal. Wild-type and Ifnar/ mice were injected s.c. with PBS, OVA, poly(I:C)+OVA, or
ARNAX+OVA (n = 2 per treatment). Data are representative of two independent experiments.
(D) IFN-g production by OVA-specific CD8+ T cells in spleen. Error bars indicate mean values ± SD.
See also Figure S1.
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ARNAX with TAA Induces Anti-tumor Immunity in PD-1/
PD-L1 Blockade-Unresponsive Tumors
Multiple human cancers display aberrant PD-L1 expression on
the cell surface (Kataoka et al., 2016), and PD-1 therapy has
mainly been applied for cancer patients with PD-L1-expressing
tumors. However, not all tumors expressing PD-L1 respond to
PD-1 blockade, and the response to PD-L1 therapy cannot be
predicted from PD-L1 levels in tumors (Hugo et al., 2016). To
determine the ability of ARNAX to induce anti-tumor CTLs that
can overcome anti-PD-1 resistance irrespective of the PD-L1
level, vaccine immunotherapy using ARNAX and tumor Ag
(OVA) was conducted against mouse EG7 (OVA-expressing
EL4 lymphoma) tumors with low or high PD-L1 levels (Kataoka
et al., 2016). We first examined in vivo targets of ARNAX in
PD-L1lo EG7-bearing mice. ARNAX stimulated splenic CD8a+
and CD8a DCs to produce IL-12p40 and TNF-a (Figure S2A).
In addition, CD11cloCD11b+ myeloid cells produced TNF-a in
response to ARNAX (Figure S2A).
PD-L1lo EG7 tumors are unresponsive to anti-PD-L1 Ab and
efficiently reduced with s.c. injection of ARNAX+OVA (Figures
3A–3C and S3A–S3C). CD8+ T cells infiltrated the tumor site,
and OVA tetramer-positive CD8+ T cells were enriched
compared to PBS injection (Figures 3D and 3E). CD11c+CD8+
T cells, an active phenotype of effector CTLs, (Takeda et al.,
Figure 2. ARNAX Induces Th1 Cytokines with Lower IFN-b Production
Wild-type mice were injected s.c. with saline (n = 4), 150 mg poly(I:C) (n = 5), or ARNAX (n = 4) (A) or i.v. with saline, 50 mg poly(I:C), or ARNAX (B) (n = 3 per
treatment). At timed intervals, blood was collected from the tail vein and cytokine levels in each sample were measured with CBA or ELISA. Data are presented as
means ± SEM. *p < 0.05, **p < 0.01, Kruskal-Wallis test with Dunn’s multiple comparison test.
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2016) were increased upon ARNAX+OVA treatment (Figure 3D).
ARNAX+OVA therapy significantly upregulated mRNA expres-
sion of the genes related to CTL activation and cytotoxicity
(Ifng, Gzmb, and Prf1) and chemokines recruiting the CTLs
(Cxcl9 and Cxcl10) in tumors (Figure 3F). Furthermore, Tbx21
and Il12b mRNA levels were upregulated, indicating Th1-type
anti-tumor immunity (Zelenay et al., 2015).
ARNAX with TAA in Combination with Anti-PD-L1 Ab
Induces Anti-tumor Immunity against PD-L1-High
Tumors
Next, we devised a combination therapy with ARNAX+OVA and
anti-PD-L1 Ab against EG7 tumors expressing high levels of
PD-L1 (Figures 4A and 4B). Anti-PD-L1 Ab treatment failed to
induce PD-L1hi tumor retardation (Figure 4C). In contrast,
ARNAX+OVA therapy suppressed tumor growth despite high
PD-L1 expression, and co-administration of anti-PD-L1 Ab
enhanced the ARNAX-mediated anti-tumor response (Fig-
ure 4C). Following ARNAX+OVA therapy, OVA-specific CD8+
T cells were modestly induced in spleen and significantly
increased in tumors, resulting in tumor regression (Figure 4D).
PD-L1 blockade did not induce OVA-specific CD8+ T cells in
spleen, while combination with ARNAX+OVA more strongly
facilitated OVA-specific CD8+ T cell priming in spleen and infil-
tration of CD8+ T cells into the tumor site than ARNAX+OVA
treatment alone. The activation marker, CD11c, and the PD-1-
positive CD8+ T cells were also increased in spleen following
combination therapy. Furthermore, intratumoral mRNA expres-
sion of Gzmb, Ifng, Prf1, and Cxcl9 was upregulated by
ARNAX+OVA and combination therapy (Figure 4E). These re-
sults collectively suggest that ARNAX serves as a priming adju-
vant to induce Ag-specific CD8+ T cells in lymphoid tissues, and
blockage of the PD-1/PD-L1 pathway augments ARNAX-medi-
ated CD8+ T cell activation and infiltration into the tumor site,
where CTL function is restored.
The augmentation of Ag-specific CD8+ T cell priming in
spleen following ARNAX+OVA/anti-PD-L1 Ab treatment was
also observed in PD-L1lo EG7 tumors, although ARNAX+OVA
single therapy was sufficient for tumor regression (Figure S3).
PD-L1 is expressed on APCs and upregulated by inflammatory
signals (Keir et al., 2008; Schietinger and Greenberg, 2014;
Joyce and Fearon, 2015; Zou et al., 2016). We examined the
in vivo expression of PD-L1 on APCs in lymphoid tissues
and tumors in PD-L1lo EG7-bearing mice. In spleen and DLN,
DC subsets including CD8a+, CD8a DCs and pDCs,
CD11b+Ly6C+ cells, and macrophages expressed low or me-
dian levels of PD-L1, while CD11b+Ly6G+ cells did not (Fig-
ure S2B). In contrast, tumor-associated DCs and CD11b+
myeloid cells all expressed high levels of PD-L1, in particular,
CD8a+ DCs, CD11b+Ly6G+, and CD11b+Ly6C+ cells dramati-
cally increased PD-L1 expression (Figure S2B). Thus, PD-1
pathway blockade may enhance TAA-specific CD8+ T cell pro-
liferation induced by ARNAX+TAA at the priming phase. The
different effect of ARNAX+OVA single therapy on PD-L1-low
or -high EG7 tumors appears to reflect PD-L1 levels on tumors,
not on tumor-infiltrated cells (Figures 3 and 4). Synergistic effect
of combination therapy was also obtained with another mouse
tumor model, MO5 (OVA-expressing B16 melanoma cell line)
(Figure S4). While anti-PD-L1 Ab or ARNAX+OVA single therapy
only partially suppressed tumor growth, combination treatment
induced additive regression of MO5 tumors (Figures S4A–S4C).
Increased level of tumor-specific CTLs in spleen and upregula-
tion of intratumoral mRNA expression of Gzmb, Ifng, Prf1,
Cxcl9, and Cxcl10 were reproducibly observed following com-
bination therapy with ARNAX+OVA and anti-PD-L1 Ab (Figures
S4D and S4E).
Notably, in mouse tumor model WT1-C1498 (an acute lym-
phoma cell line overexpressing WT1), ARNAX significantly sup-
pressed tumor growth without co-administration of TAA (Figures
S5A–S5D). CD8+ T cells infiltrated into the tumors and CD8+ T
effector population (CD62LCD11c+PD-1+) were increased (Fig-
ure S5E). PD-L1 blockade elicits tumor rejection regardless of
combination with ARNAX. In these settings, CD8+ T cells infil-
trated the tumor site, and CD8+ T effector population was
increased in both spleen and tumors (Figure S5E). An intriguing
notion is that spontaneous tumor-specific CD8+ T cell priming
occurs in lymphoid tissues, which is enhanced by PD-L1
blockade, resulting in CD8+ T cell infiltration into tumors. ARNAX
appears to boost Ag-specific CTL priming together with intrinsic
tumor Ag released from damaged tumor cells (Kroemer et al.,
2013).
ARNAXTherapy Changes the Tumor-Infiltrating Immune
Cell Population from Immune Suppressive to Effective
Tumor growth is promoted by inflammation in the tumor micro-
environments infiltrated by immune cells (Coussens et al.,
2013; Mantovani et al., 2008). We assessed the tumor-infiltrating
immune cell population in ARNAX-treated EG7 tumors (CD45.2+)
following poly(I:C)+OVA or ARNAX+OVA treatment using
CD45.1 congenic mice as the host (Figures 5A, S6A, and
S6B). Administration of ARNAX or poly(I:C) together with OVA
led to a significant increase in the CD8+ T cell proportion of
CD45.1+ cells within the tumor region (PBS, 5%, ARNAX or
poly(I:C)+OVA, >20%) as well as a mild increase in the NK cell
population (Figure 5B). CD4+ T, NKT, and B cells represented a
minor population in tumor regions (Figures 5B and S6C). Among
DC subsets that were also minor populations, the CD8a+ DC
population was largely increased following ARNAX or poly
(I:C)+OVA therapy, while the proportion of pDC, CD103+ DC,
and CD4+ DC remained unchanged (Figures 5C, S6D, and
S6E). Conversely, the CD11b+ myeloid cell population account-
ing for >60% CD45.1+ cells in the untreated tumor region was
decreased by ARNAX treatment (Figure 5D). Notably, among
the CD11b+ myeloid cells (including Ly6G+, Ly6C+, and F4/80+
cells), CD11b+Ly6G+ cells, referred to as granulocytic myeloid-
derived suppressor cells (G-MDSC) or tumor-associated neutro-
phils, were markedly reduced by ARNAX or poly(I:C)+OVA
therapy (Figure 5D) (Peranzoni et al., 2010; Youn et al., 2008).
The proportion of tumor-infiltrating myeloid cells depends on
the tumor cell type. MO5 tumors are CD11b+Ly6G+-low and
CD11b+Ly6C+-high, which remained unchanged, but CD8+
T cells and CD8a+ DCs were increased in the tumors following
ARNAX therapy (Figure S4F). Thus, ARNAX appears to facilitate
infiltration of Th1-type immune cells into the tumor site, accom-
panied by reduction of immunosuppressive myeloid cell
recruitment.
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Figure 3. ARNAX and TAA Therapy Induces Tumor Regression in PD-1 Blockade-Unresponsive EG7 Tumors
(A) PD-L1 expression on PD-L1lo EG7 cells. Shaded and open histograms represent isotype control and PD-L1 staining, respectively.
(B) Scheme of ARNAX+OVA therapy in PD-L1lo EG7 tumors.
(C) Mice were challenged with PD-L1lo EG7 cells, and 7 days later they were injected s.c. with control PBS (blue) or ARNAX+OVA (red). Tumor size was evaluated
in each group. Error bars indicate means ± SEM; n = 5 per group. **p < 0.01 with Student’s t test.
(D–F) On day 14, tumors were harvested from PBS- or ARNAX+OVA-treated mice and analyzed. (D) Flow cytometry analysis of tumor-infiltrating CD8+ T cells
(left), OVA-specific CD8+ T cell proliferation (center), and CD11c expression on CD8+ T cells (right). n = 5 per group. (E) Left: representative confocal images of
tumor-infiltrating CD8+ cells (green) in PBS- or ARNAX+OVA-treatedmice. Scale bar, 100 mm. Right: the number of tumor-infiltrating CD8+ cells per 0.2 mm2 field
was counted in random confocal images from two to three animals per group (PBS, 20 images; ARNAX+OVA, 16 images). (F) Gene expression analysis in tumors
from PBS- or ARNAX+OVA-treated mice. Indicated mRNA levels were measured using qPCR and normalized to Gapdh. Error bars indicate means ± SEM; n = 5
per group. *p < 0.05, **p < 0.01 with Student’s t test.
See also Figures S2 and S3.
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ARNAX Induces Th1-type Anti-tumor Immunity in the
Tumor Microenvironment
To examine ARNAX-mediated anti-tumor immunity, comprehen-
sive gene expression analysis was performed via RNA
sequencing of whole EG7 tumors treated with PBS, ARNAX+
OVA, or poly(I:C)+OVA. To evaluate early and late tumor re-
sponses, we harvested whole tumor tissues on 18 hr and
6 days after adjuvant+OVA injection (Figures 6A and S7A). On
day 8 (18 hr after the treatment), we observed no differences in
tumor growth among the groups with PBS, ARNAX+OVA, and
poly(I:C)+OVA (Figure S7B). Overall, no significant variations in
gene expression were observed among the three groups under
the 18 hr conditions (Figure S7C). Some of IFN-inducible genes,
however, were significantly upregulated in the poly(I:C)+OVA
group (Figures S7D and S7E) but not the ARNAX+OVA group,
which showed no significant variation in these gene expressions
compared to the PBS group (data not shown), suggesting that
ARNAX barely induces type I IFN even in the tumor microenviron-
ment.On day 13, tumor growthwas similarly retarded in response
to ARNAX+OVAand poly(I:C)+OVA therapy (Figure 6B). Concom-
itantly, numerous genes related to anti-tumor immunity were up-
regulated in the ARNAX+OVA and poly(I:C)+OVA groups (Figures
6C and 6D). In particular, chemokine genes, includingCcl4,Ccl5,
Ccl8, andCcl27, were significantly increased in response to TLR3
agonists (Figure 6D). Their receptor genes are expressed in DCs,
NK, and T cells (Bachmann et al., 2006), which may account for
accumulation of CD8a+ DCs, T cells, and NK cells in the tumors
(Figures 5B and 5C). In addition, NK/T cell function-related genes
and cell adhesion genes, such as Vcam1, were upregulated (Fig-
ure 6D). On the other hand, NK cell inhibitory receptorKlra1 (Ly49
receptor), and Tnfsf4 (OX40L) involved in Th2 cell differentiation,
were downregulated with ARNAX/poly(IC)+OVA therapy. Ag-pre-
senting cell-related genes were augmented to accelerate T cell
priming. Significant correlation between the expression levels of
these genes on day 13 and tumor growth retardation was
observed (Figures 6B and 6D). No significant variations in gene
expression were observed between ARNAX+OVA and poly
(I:C)+OVA treatment groups on day 13 (Figure 6E). Taken
together, these results strongly suggest that ARNAX therapy
modulates the tumor microenvironment and elicits Th1-type
anti-tumor immunity with minimal essential cytokine induction.
ARNAX Induces Ag-Specific CTLs in Human Peripheral
Blood Mononuclear Cells
To determine whether ARNAX induces Ag-specific CD8+ T cell
priming in humans as observed for mice, we employed a cyto-
megalovirus (CMV)-tetramer assay using human peripheral
bloodmononuclear cells (PBMCs). PBMCs isolated from individ-
ual healthy donors were stimulated with ARNAX or poly(I:C) with
or without the CMV pp65 protein. In the absence of Ag (CMV
pp65), poly(I:C) and ARNAX did not significantly promote CMV
pp65-specific CD8+ T cell expansion (Figure 7). In the presence
of CMV pp65 Ag, pp65-specific CD8+ T cells were expanded
even without adjuvant, to different extents among individuals.
Remarkably, the proportion of pp65 tetramer-positive cells was
considerably increased upon simultaneous stimulation with
adjuvant and pp65 Ag, compared to Ag only. The degree of
pp65-specific CD8+ T cell expansion induced by ARNAX+Ag
was comparable to that induced by poly(I:C)+Ag. These results
support the ability of ARNAX to induce Ag-specific CD8+
T cells in in vitro human PBMC systems.
DISCUSSION
Immunotherapy with PD-1/PD-L1 blockade has provided a
breakthrough in cancer treatment. However, additional thera-
peutic strategies are necessary to improve the remission rates
in non-responding patients with solid tumors. Here, we aimed
to develop a safe vaccine immunotherapy for cancer that effec-
tively implements anti-PD-L1 immunotherapy. ARNAX and TAA
bimodally contribute to tumor regression by inducing tumor-spe-
cific CTLs in lymphoid tissues and facilitating their infiltration into
the tumor site. ARNAX satisfies cross-priming of CTL by DCs in
lymphoid tissues with minimal essential cytokine induction in
contrast to poly(I:C). Type I IFN-signaling in DCs is indispensable
for CD8+ T cell priming (Fuertes et al., 2011, 2013; Pantel et al.,
2014): even locally secreted type I IFN is sufficient for ARNAX-
mediated cross-priming. In addition, ARNAX induces Th1-type
chemokines, CXCL9 and CXCL10, that recruit CXCR3+CD8+
T cells to the tumor site. CXCR3 levels on T cells are high in
DLNs while low in tumors, which allows the T cells to stay in tu-
mors (Sistigu et al., 2014). These innate features of ARNAX can
overcome anti-PD-1 resistance that is associated with insuffi-
cient anti-tumor CD8+ T cell priming and limited tumor CD8+
T cell infiltration (Tumeh et al., 2014; Sharma and Allison,
2015b). ARNAX administered with TAA facilitates PD-L1 Ab ac-
tivity in tumor regression in mouse implant tumor models. In
the effector phase, tumor cells and tumor-associated APCs ex-
press PD-L1 to prevent CTL attack. In the priming phase, PD-L1
is expressed on Ag-presenting DCs and macrophages. Curiel
et al. (2003) reported that tumor environmental factors upregu-
lates PD-L1 expression on DCs in tumors and tumor draining
Figure 4. ARNAX+OVA Synergistically Induce Anti-tumor Immunity with PD-L1 Ab in PD-L1hi EG7 Tumors
(A) Comparison of surface PD-L1 expression between PD-L1lo and PD-L1hi EG7 cells. Dotted and solid lines signify PD-L1 expression in PD-L1lo EG7 and PD-L1hi
EG7 cells, respectively. The shaded histogram represents isotype control Ab staining.
(B) Scheme of combination therapy of ARNAX+OVA and anti-PD-L1 Ab in PD-L1hi EG7 tumors.
(C) PD-L1hi EG7-bearing mice were treated with PBS (n = 4) or ARNAX+OVA (n = 6) in combination with anti-PD-L1 Ab or isotype control Ab as shown in (B), and
tumor sizes were evaluated in each group. Error bars indicate means ± SEM. *p < 0.05 with Student’s t test.
(D) CD8+ T cell density, OVA-specific CD8+ T cell proliferation, and the proportion of CD8+ T cells expressing CD11c or PD-1 in spleen (top) and intratumors
(bottom).
(E) Gene expression analysis in tumors harvested from tumor-bearing mice on day 13 in each group. Indicated mRNA levels were measured with qPCR and
normalized to Gapdh. Error bars indicate means ± SEM; n = 4 or 6 per group. *p < 0.05, **p < 0.01, ***p < 0.001 with Kruskal-Wallis test with Dunn’s multiple
comparison test (D and E).
See also Figures S2–S5.
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LN, which impairs DC-mediated T cell activation. Hence, block-
ing of PD-L1 promotes ARNAX-driven proliferation of Ag-spe-
cific CD8+ T cells and tumor cytotoxicity in the priming and
effector phases, respectively.
Anti-tumor CD8+ T cells induced by ARNAX exhibit an effector
T cell phenotype (Kaech and Cui, 2012), whereby cell surface
CD11c and PD-1 are increased concomitantly with cytotox-
icity-related genes, Gzmb, Prf1, and Ifng. In addition, the tran-
scription factor, Tbx21, is upregulated to skew effector T cells.
Data from RNA sequencing (RNA-seq) revealed that Th1-type
anti-tumor immunity is established in EG7 tumor microenviron-
ment following ARNAX/TAA therapy. In particular, chemokines
related to the recruitment of CD8a+ DCs, T and NK cells, many
NK/T cell function-related molecules, and Ag-presenting cell-
related molecules are significantly increased in tumors following
ARNAX+OVA treatment. Interestingly, the expression levels of
these genes and tumor growth retardation were significantly
correlated. Thus, efficient induction of Th1-type anti-tumor
immunity requires DC-priming adjuvant supporting TAA. ARNAX
and poly(I:C) brought similar gene expression profiles in the
tumor microenvironment. However, poly(I:C) induces systemic
cytokinemia in i.v. and i.p. injection, while ARNAX does not in
any route of injection. Furthermore, expression of type I IFN
and IFN-inducible genes that trigger inflammation in tumors
was barely induced following ARNAX+OVA treatment.
Innate-resistance features of non-responding tumors and
immunosuppressive tumor microenvironments are reported to
negatively affect anti-PD-1 therapy (Zelenay et al., 2015; Hugo
et al., 2016; De Henau et al., 2016). ARNAX therapy participates
in modulation of the tumor microenvironment to drive effective
anti-tumor immunity. Ultimately, ARNAX licenses DCs in tumors
and DLN to activate functional tumor-specific CTLs and relieve
anti-PD-L1 unresponsiveness. In MO5 and WT1-C1498 tumor
models, anti-PD-L1 Ab was partially or highly effective in tumor
regression, suggesting the preexistence of tumor-reactive
CTLs. Indeed, intratumor CD8+ T cell population in PBS-treated
MO5 or WT1-C1498 tumors was higher than that in PBS-treated
EG7 tumors where tumor-reactive CTLs might be less present
(10% versus 5%).
Somatic mutation and their associated antigen in the tumor
genome cannot be determined without genetic analysis. TAAs
are mounted on MHC under restriction of haplotypes. Priming
adjuvants trigger TAA-specific CTLs in the context of MHC re-
striction. Investigations of TAA-selecting programs are report-
edly in progress. Application of ARNAX to well-established
peptide vaccine immunotherapy and/or combination with PD-1
blockade appears to present a promising strategy to overcome
PD-1 resistance. In contrast to poly(I:C) that has been used for
earlier clinical trials (Levine et al., 1979; Lampkin et al., 1985),
ARNAX is non-toxic features and may prevent the onset of se-
vere adverse effects that occur due to systemic inflammatory
cytokine/type I IFN production. Ex vivo studies using human
PBMCs showed that ARNAX and Ag induced Ag-specific CTL
priming and proliferation. Because the CMV-pp65 assay has lim-
itations in translational value, in future experiments we will
design the in vitro assay to detect TAA-specific CTLs. In sum-
mary, we have presented an approach using the priming adju-
vant that promotes TAA-specific expansion of CTLs and effec-
tive tumor regression in combination with checkpoint inhibitors.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from CLEA Japan, and C57BL/6(CD45.1) mice
were from Sankyolabo Co. Ticam-1/ and Mavs/ mice were generated in
our laboratory and backcrossed more than eight times to adapt the C57BL/6
background. Tlr3/ and Myd88/ mice were kindly provided by Dr. S. Akira
(Osaka University) and Irf3/, Irf7/ and Ifnar/ mice by Dr. T. Taniguchi
(University of Tokyo). Irf3/Irf7 double knockout mice were generated in our lab-
oratory by crossing Irf3/with Irf7/mice. Mice were maintained under spe-
cific pathogen-free conditions in the animal facility of Hokkaido University
Graduate School of Medicine. All animal experiments were approved by the
Institutional Animal Care and Use Committee of Hokkaido University and per-
formed in compliance with their guidelines.
Cells, Reagents, and Antibodies
EG7 cells were purchased from ATCC and cultured in RPMI1640 supple-
mented with 10% FCS, 55 mM 2-ME, 10 mM HEPES, 1 mM sodium pyruvate,
50 IU penicillin/50 mg/mL streptomycin, and 0.5mg/mLG418. PD-L1loEG7 and
PD-L1hiEG7 (mock- and sgPd-l1-transfected EG7) cells were prepared as
described earlier (Kataoka et al., 2016). MO5 (Ryu et al., 2014) and WT1-
C1498 were kindly provided by Dr. H. Udono (Okayama University) and H. Su-
giyama (Osaka University), respectively. Poly(I:C) was purchased from Amer-
shamBiosciences. Endotoxin-free OVA (EndoOVA)was obtained fromHyglos.
OVA257–264 peptide (SL8), WT1 peptide (Db126), OVA (H2K
b-SL8) tetramer,
HCMV pp65 peptides, and HLA-A*02:01 and HLA-A*24:02 CMV pp65 tetra-
mers were purchased from MBL. HCMV pp65-recombinant protein and hu-
man FcR blocking reagent were from Miltenyi Biotec. ARNAX was generated
as described (Matsumoto et al., 2015), with slight modifications, whereby
anti-sense 140-mer RNAwas successively generated with an RNA synthesizer
(GeneDesign). The antibodies used for flow cytometry analysis are listed in
Table S1.
In Vivo Cross-Priming Assay
Wild-type (WT) or knockout mice (9–12 weeks) were injected subcutaneously
(s.c.) with 50 mL of 100 mg EndoOVA in PBS () with or without 50 mL of 60 mg
ARNAX twice per week. PBS () (100 mL) was used as the control. Spleen and
inguinal LN cells were harvested 4 days after the last adjuvant injection and
OVA-specific CD8+ T cell proliferation was analyzed with the tetramer assay.
To evaluate cytokine production, splenocytes (2 3 106/200 mL/well) were
cultured for 3 days in the presence of 100 nM OVA peptide (SL8: SIINFEKL)
Figure 5. TLR3 Adjuvant Promotes Accumulation of CD8+ T Cells and CD8a+ DCs into Tumors
(A) Scheme of TLR3 adjuvant therapy in EG7-bearing congenic mice. C57BL/6(CD45.1) mice were inoculated with EG7 (CD45.2+ lymphoma) cells and treated
with PBS (n = 3), poly(I:C)+OVA (n = 4), or ARNAX+OVA (n = 4) on day 7. Tumor growth is shown on the right.
(B) Tumors were harvested on day 12 and single cell suspensions prepared for each sample. Cells were mixed in each group and subjected to flow cytometry.
Left: flow cytogram of CD8+ T, NKT, and NK cell populations gated on CD45.1+ cells. Right: proportion of each lymphocyte population in tumor-infiltrating
CD45.1+ cells.
(C) Left: flow cytogram of CD8a+ DC population gated on conventional DCs (cDCs). Right: proportion of the DC subset in tumor-infiltrating CD45.1+ cells or cDCs.
(D) Left: flow cytogram of CD11b+Ly6G+, CD11b+Ly6C+, andmacrophage population gated on CD45.1+ cells. Right: proportion of eachmyeloid cell population in
tumor-infiltrating CD45.1+ cells. Numerical values represent the percentage of gated cells.
See also Figure S6.
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Figure 6. ARNAX Promotes Th1-type Anti-tumor Immunity
(A) EG7-bearing mice were treated with PBS, poly(I:C)+OVA or ARNAX+OVA on day 7. Tumors were harvested on day 13 (n = 3 per group).
(B) Tumor growth of each mouse.
(C) Gene expression (log10 normalized read count) in tumors harvested from PBS- or ARNAX+OVA-treated mice on day 13; diagonal line indicates change in
expression of 1-fold. Colors indicate significant (adjusted p value, <0.05) upregulation (red; n = 522) or downregulation (blue; n = 105) of expression.
(D) Heatmap illustrating the relative expression patterns of genes in whole tumors from EG7-bearing mice treated with PBS, ARNAX+OVA, or poly(I:C)+OVA on
day 13.
(E) Gene expression (log10 normalized read count) in tumors harvested from ARNAX+OVA- or poly(I:C)+OVA-treated mice on day 13. Diagonal line indicates
change in expression of 1-fold.
See also Figure S7.
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or control WT1 peptide (Db126: RMFPNAPYL) and IFN-g production was
analyzed with the cytometric bead array (CBA).
In Vivo Mouse Cytokine Assay
Female C57BL/6 mice 7–8 weeks of age were injected s.c. with 200 mL of
150 mg poly(I:C) or ARNAX or intravenously (i.v.) with 200 mL of 50 mg poly(I:C)
or ARNAX, and blood was collected from the tail veins at the indicated times.
Saline (200 mL) was used as a control. Cytokine levels in sera were measured
using CBA. IFN-b and IP-10 levels were quantified with ELISA.
Tumor Challenge and ARNAX Therapy
Female C57BL/6 mice 7 weeks of age were injected s.c. with 200 mL of 23 106
wild-type EG7, PD-L1loEG7, or PD-L1hiEG7 cells in PBS (). Tumor volumes
were measured at regular intervals using a caliper and calculated by the
following formula: tumor volume (mm3) = (long diameter) 3 (short diameter)2
3 0.52. When the average tumor volume reached 600 mm3 (day 7), 100 mL
of 100 mg EndoOVA in PBS () with or without 100 mL of 60 mg poly(I:C) or
ARNAX was injected s.c. around the tumor. PBS () (200 mL) was used as a
control. On day 13 or 14, spleens and tumorswere excised from tumor-bearing
mice and further analyzed. For PD-L1 blockade, tumor-bearing mice were in-
jected i.p. with 200 mg anti-mouse PD-L1 monoclonal antibody (mAb)
(10F.9G2; Bio X Cell) or rat IgG2b isotype control (LTF-2; Bio X Cell) on days
5, 7, 9, and 11.
Analysis of EG7 Tumors
For confocal microscopy, 4% paraformaldehyde-fixed frozen tumor sections
were stained with APC-anti-mouse CD8a mAb and DAPI and analyzed under a
LSM510 META microscope (Zeiss). The number of CD8+ cells infiltrating
tumors was counted from randomly selected fields (0.2 mm2 per field). Tumors
were finely minced and treated with 25 mg/mL collagenase I (Sigma-Aldrich),
collagenase IV (Sigma-Aldrich), 12.5 mg/mL hyaluronidase (Sigma-Aldrich), and
5 mg/mL DNase I (Roche) in Hanks’ balanced salt solution (Sigma-Aldrich) at
33C for 15 min for flow cytometry analysis. Red blood cells were lysed with
ACK lysis buffer. Cells were stained with antibodies and analyzed on FACSAria
II (BD Biosciences). Data analysis was performed with FlowJo software (Tree
Star). The gating strategies are presented in Figure S6. For analysis of gene
Figure 7. ARNAX Induces Ag-Specific CD8+
T Cells in Human PBMCs
Human PBMCs from healthy donors were stimu-
lated with saline, 20 mg/mL poly(I:C), or ARNAX
with or without CMV pp65 recombinant protein
and cultured for 8–14 days. Proliferation of CMV
pp65-specific CD8+ T cells was evaluated with the
tetramer assay and analyzed on FACSAria II. The
numerical value in each panel indicates the per-
centage of CMV pp65 tetramer+ cells in CD8+
T cells.
expression in tumors, total RNAwas extractedusing
TRIzol reagent (QIAGEN) and reverse-transcribed
with a high capacity cDNA Reverse Transcription
kit (Applied Biosystems) and random primers, ac-
cording to the manufacturer’s instructions. qPCR
was performed using specific primers (Table S2)
and the Step One Real-time PCR system (Applied
Biosystems).
RNA-Seq Analysis
EG7-implanted mice were treated with PBS, pol-
y(I:C)+OVA or ARNAX+OVA on day 7. Tumor tis-
sues harvested on day 8 or 13 were homogenized
in TRIzol regent and total RNA was extracted ac-
cording to the manufacturer’s instructions. Bio-
analyzer (Agilent) was used to validate quality
and quantity of purified RNA. Library construction for RNA-seq was per-
formed with the TruSeq Stranded mRNA LT Sample Prep Kit (Illumina) ac-
cording to the manufacturer’s instructions, and the product was subjected
to Hiseq 2500 with the 100 bp single-end protocol (Illumina). Acquired reads
were mapped on mouse genome GRCm38 by Tophat2 v2.1.1 (Kim et al.,
2013), with the annotation described in gtf release-85 allowing multiple hits
up to 100. Multiple mapped reads were segregated and distributed in a
random manner using an in-house script. Reads on protein coding genes
were counted using HTSeq (Anders et al., 2015) with the gtf using only the
protein-coding feature. Differentially expressed genes were examined by
DESeq (Anders and Huber, 2010). Genes of interest on pathways annotated
in KEGG were selected in cases where expression levels were significantly
different (adjusted p value <0.05 and ±2-fold) among ARNX+OVA (day 13)
and PBS (day 13) groups. Read counts were normalized by total mapped
reads and fit on standard normal distribution to depict heatmaps.
Induction of CMV-Specific CD8+ T Cells in Human PBMCs
Human PBMCs were isolated from the peripheral blood of healthy donors with
informed consent. The protocol was approved by the Ethical Committee of
Hokkaido University Graduate School of Medicine. Cells (0.5–1 3 107/mL)
were suspended in RPMI1640 supplemented with 5% auto-plasma, 55 mM
2-ME, and 50 IU penicillin/50 mg/mL streptomycin and stimulated with saline,
20 mg/mL poly(I:C), or ARNAXwith or without HCMV pp65 recombinant protein
on a 96-well plate. At 48 hr after culture, equal volumes of medium containing
recombinant human IL-2 (100 U/mL) were added to the wells and further
cultured for 8–14 days. Half of the medium was exchanged with fresh medium
containing 50 U/mL hIL-2 twice a week. Proliferation of CMV pp65-specific
CD8+ T cells was measured with HLA-A*02:01 or HLA-A*24:02 CMV pp65
tetramer according to the manufacturer’s instructions (MBL) and analyzed
on FACSAria II. Human data were anonymized employing the methods for
the protection of personal information recommended by theMinistry of Health,
Labor and Welfare, Japan.
Statistical Analysis
The significance of differences between two groups was determined with the
Student’s t test. Kruskal-Wallis test with Dunn’s multiple comparison was
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performed for more than two groups. Error bars represent SD or SEM between
samples.
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